Recent news highlights Owlet's narrower Q4 loss with year-over-year revenue growth, management changes with the appointment of Kurt Workman as CEO, and expectations of a decline in Q1 earnings.

• Owlet reported a narrower Q4 loss than expected and year-over-year revenue growth [N5].
• The company reported Q4 2025 earnings and held an earnings call discussing results and outlook [N6][N7].
• Kurt Workman was appointed President and CEO effective April 6, 2026, succeeding Jonathan Harris [S18].
• News previews indicate expectations of a decline in Q1 earnings [N1].
• Owlet received a relative strength alert in early April 2026, indicating market interest [N3].

Owlet has demonstrated year-over-year revenue growth and has narrowed losses in recent quarters, indicating operational improvements. The appointment of a CEO with deep company knowledge may support strategic execution. The company's liquidity position, with a current ratio of 1.85 and cash reserves, provides some runway to pursue growth initiatives. Experienced board members with backgrounds in healthcare and technology may facilitate strategic partnerships and innovation. If the company manages tariff impacts and capital needs effectively, it could strengthen its market position.

Owlet has a history of recurring operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern. The company faces significant risks from tariffs and trade restrictions that increase costs and pressure margins. Additional capital raises may dilute existing shareholders and may not be available on favorable terms. Macroeconomic factors such as inflation and recession could reduce demand for its products. Failure to secure adequate financing or manage costs could materially and adversely affect its business and financial condition.

Owlet's moat appears to be based on its specialized healthcare technology products and its established supply chain relationships in Southeast Asia. The company benefits from experienced leadership with deep industry knowledge and a board with diverse expertise. However, the presence of tariffs and trade restrictions, along with the company's history of operating losses, suggest that its competitive advantages may be challenged by external economic factors and capital constraints. The company's ability to innovate and manage costs in a competitive healthcare technology market will be critical to maintaining its position.

• Going Concern Risk: Owlet has recurring operating losses and negative cash flows, with substantial doubt about its ability to continue as a going concern within one year after the latest financial statements.
• Capital Raising Risk: The company may need to raise additional capital to support operations and strategic plans, which may not be available on acceptable terms or at all, potentially diluting existing shareholders.
• Tariff and Trade Risk: Tariffs on imports from Vietnam and Thailand have increased costs of goods sold, adversely impacting profitability and competitiveness. Changes in trade policies could further affect operations.
• Macroeconomic Risk: Inflation, recession, and changes in consumer spending could reduce demand for Owlet's products, affecting revenues and financial performance.
• Operational Risk: Dependence on manufacturing in Southeast Asia exposes the company to supply chain disruptions and tariff impacts, which could affect product availability and costs.

• Owlet, Inc. is a Delaware corporation headquartered in Lehi, Utah.
• The company is publicly traded on the New York Stock Exchange under the ticker OWLT.
• Owlet's fiscal year ends December 31; the latest annual report is for FY 2025, filed as a 10-K/A on 2026-04-30 [S1].
• As of December 31, 2025, Owlet had cash and cash equivalents of $35.46 million and current assets of $81.92 million, with current liabilities of $44.24 million, resulting in a current ratio of 1.85 and a cash ratio of 0.8 [S1].
• Owlet reported a net loss of $39.68 million for FY 2025 and a basic EPS of -$2.31 for the same period [S1].
• The company has a history of recurring operating losses and negative cash flows from operations since inception, raising substantial doubt about its ability to continue as a going concern [S2].
• Owlet's management includes Kurt Workman as President and CEO as of April 6, 2026, who previously co-founded the company and served as CEO until October 2025 [S1, S18].
• The company sources products primarily from Thailand and Vietnam, with tariffs impacting cost of goods sold, including a 20% tariff on imports from Vietnam and a 19% tariff on products from Thailand [S4, S5, S14, S19].
• Owlet's Q4 2025 results showed a narrower loss than expected and year-over-year revenue growth [N5, N7].
• The company faces risks related to tariffs, trade restrictions, and the need for additional capital to support operations and strategic plans [S2, S4, S5, S6].
• Owlet's board of directors includes members with significant experience in healthcare, technology, finance, and venture capital [S1].
• The company has disclosed management changes and compensatory arrangements publicly, including severance and employment agreements [S15, S16, S18].
• Recent news indicates expectations of a decline in Q1 earnings and ongoing operational challenges [N1].